White House Psychedelics Executive Order Accelerates Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy ATAI?
Source: Newsfilter
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATAI
Wall Street analysts forecast ATAI stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.030
Low
10.00
Averages
13.00
High
16.00
Current: 4.030
Low
10.00
Averages
13.00
High
16.00
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Directs Acceleration of Psychedelic Drug Reviews
- Stock Surge: Atai Beckley's shares jumped 21.59% to close at $0.87 following Trump's directive to accelerate psychedelic drug reviews, reflecting strong market confidence in new drug development.
- Regulatory Acceleration: Trump's executive order aims to shorten the regulatory evaluation timelines for certain psychedelic drugs, with the FDA potentially completing reviews for breakthrough-designated therapies in as little as one to two months, expediting market entry.
- Optimistic Industry Outlook: Industry leaders assert that Trump's order validates the significance of psychedelic research and is expected to facilitate faster access to promising new treatments for patients, addressing the growing mental health needs.
- Clinical Trial Progress: Atai Beckley's investigational nasal spray BPL-003 has received breakthrough therapy designation and demonstrated promising results in Phase 2 studies, with plans to initiate Phase 3 trials later this year, further solidifying its leadership position in the psychedelic market.
See More
Atai Beckley Shares Surge 21% Following Trump’s Psychedelic Treatment Review Acceleration
- Regulatory Review Acceleration: President Trump has directed U.S. health regulators to expedite reviews of psychedelic treatments for severe mental illnesses, potentially allowing drugs with breakthrough therapy designations to complete reviews in as little as one to two months, significantly shortening the time to market.
- Stock Surge: Atai Beckley (NASDAQ: ATAI) shares jumped over 21% following the announcement, with a market cap of approximately $1.8 billion, reflecting investor optimism about the psychedelic drug market's future.
- Breakthrough Therapy Progress: Atai Beckley is developing a nasal spray, BPL-003, for treatment-resistant depression, which has received breakthrough therapy designation and showed promising results in Phase 2 studies, with Phase 3 trials expected to begin later this year.
- Industry Outlook: Industry leaders believe Trump's executive order validates the importance of psychedelic research and could accelerate the delivery of new drugs to patients, thereby bringing new hope and opportunities to mental health treatment.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
Trump Directs Acceleration of Psychedelic Drug Reviews
- Stock Surge: Atai Beckley's shares jumped 21.59% to close at $0.87 following Trump's directive to accelerate psychedelic drug reviews, reflecting strong market confidence in new drug development.
- Regulatory Acceleration: Trump's executive order aims to shorten the regulatory evaluation timelines for certain psychedelic drugs, with the FDA potentially completing reviews for breakthrough-designated therapies in as little as one to two months, expediting market entry.
- Optimistic Industry Outlook: Industry leaders assert that Trump's order validates the significance of psychedelic research and is expected to facilitate faster access to promising new treatments for patients, addressing the growing mental health needs.
- Clinical Trial Progress: Atai Beckley's investigational nasal spray BPL-003 has received breakthrough therapy designation and demonstrated promising results in Phase 2 studies, with plans to initiate Phase 3 trials later this year, further solidifying its leadership position in the psychedelic market.
See More
Atai Beckley Shares Surge 21% Following Trump’s Psychedelic Treatment Review Acceleration
- Regulatory Review Acceleration: President Trump has directed U.S. health regulators to expedite reviews of psychedelic treatments for severe mental illnesses, potentially allowing drugs with breakthrough therapy designations to complete reviews in as little as one to two months, significantly shortening the time to market.
- Stock Surge: Atai Beckley (NASDAQ: ATAI) shares jumped over 21% following the announcement, with a market cap of approximately $1.8 billion, reflecting investor optimism about the psychedelic drug market's future.
- Breakthrough Therapy Progress: Atai Beckley is developing a nasal spray, BPL-003, for treatment-resistant depression, which has received breakthrough therapy designation and showed promising results in Phase 2 studies, with Phase 3 trials expected to begin later this year.
- Industry Outlook: Industry leaders believe Trump's executive order validates the importance of psychedelic research and could accelerate the delivery of new drugs to patients, thereby bringing new hope and opportunities to mental health treatment.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
